selected publications
-
Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response.
Clinical lymphoma, myeloma & leukemia.
2019
Review
GET IT
Times cited: 8 - Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. Leukemia research. 2019 Academic Article GET IT
-
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood.
2018
Academic Article
GET IT
Times cited: 213 -
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
2018
GET IT
Times cited: 173 -
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
The New England journal of medicine.
2018
Academic Article
GET IT
Times cited: 889 -
Time to repeal and replace response criteria for acute myeloid leukemia?.
Blood reviews.
2018
Review
GET IT
Times cited: 45 -
Widespread use of measurable residual disease in acute myeloid leukemia practice.
Leukemia research.
2018
Academic Article
GET IT
Times cited: 6 - Minimal Residual Disease in Acute Myeloid Leukemia: Prognostication and Pitfalls. Journal of oncology practice. 2017 Comment GET IT
-
Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2017
Academic Article
GET IT
Times cited: 12 -
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Blood.
2017
Academic Article
GET IT
Times cited: 970 -
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 82 -
Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction.
The oncologist.
2017
Academic Article
GET IT
Times cited: 21 -
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.
Acta haematologica.
2016
Academic Article
GET IT
Times cited: 12 -
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia.
Leukemia research.
2016
Academic Article
GET IT
Times cited: 13 -
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.
Leukemia.
2016
Academic Article
GET IT
Times cited: 45 -
Acute myeloid leukemia masquerading as hepatocellular carcinoma.
2016
GET IT
Times cited: 322 -
Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
2016
Academic Article
GET IT
Times cited: 9 -
Emerging therapeutic drugs for AML.
Blood.
2015
Review
GET IT
Times cited: 148 -
Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015
Review
GET IT
Times cited: 30 -
IDH2 inhibition in AML: Finally progress?.
Best practice & research. Clinical haematology.
2015
Review
GET IT
Times cited: 47 -
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center.
British journal of haematology.
2015
Academic Article
GET IT
Times cited: 13 -
Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy.
British journal of haematology.
2015
Academic Article
GET IT
Times cited: 21 -
Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L.
Current opinion in hematology.
2015
Review
GET IT
Times cited: 50 -
Acute promyelocytic leukemia in children and adolescents.
Acta haematologica.
2014
Review
GET IT
Times cited: 14 - Searching the central nervous system for relapsed acute promyelocytic leukemia. Leukemia & lymphoma. 2013 Comment GET IT
-
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.
Leukemia research.
2013
Academic Article
GET IT
Times cited: 78 - Persistent problems with persistent disease: minimal residual disease in acute myelogenous leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Comment GET IT
-
Remission induction in acute myeloid leukemia.
International journal of hematology.
2012
Review
GET IT
Times cited: 16 -
Provocative pearls in diagnosing and treating acute promyelocytic leukemia.
Oncology (Williston Park, N.Y.).
2012
Review
GET IT
Times cited: 6 -
Novel and emerging drugs for acute myeloid leukemia.
Current cancer drug targets.
2012
Review
GET IT
Times cited: 13 -
Does arsenic trioxide impact fertility?.
Leukemia & lymphoma.
2012
Comment
GET IT
Times cited: 3 -
Hepatitis C and non-Hodgkin lymphoma: the clinical perspective.
Hepatology (Baltimore, Md.).
2012
Review
GET IT
Times cited: 47 -
Curing all patients with acute promyelocytic leukemia: are we there yet?.
Hematology/oncology clinics of North America.
2011
Review
GET IT
Times cited: 17 -
The coagulopathy of acute promyelocytic leukaemia revisited.
Best practice & research. Clinical haematology.
2009
Review
GET IT
Times cited: 117 -
New therapeutic options in gastrointestinal stromal tumors.
Oncology (Williston Park, N.Y.).
2008
Review
GET IT
Times cited: 1